Shares of Compugen (CGEN) added ~16% in the premarket on Wednesday after the Israel-based biotech announced an agreement with ...

Shares of Compugen rose after the company agreed to monetize a portion of future royalties from its rilvegostomig drug to AstraZeneca for up to $90 million. The stock rose 12% to $1.67 in premarket ...

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that it has agreed ...

Shares of Compugen Ltd. (NASDAQ:CGEN) rose 12.8% in premarket trading on Wednesday after the company unveiled a strategic ...

Israeli drug discovery and development company Compugen (Nasdaq: CGEN; TASE: CGEN) today announced changes in its ...

Rilvegostomig is a first-in-class dual-checkpoint bispecific therapy that delivers coordinated PD-1 and TIGIT blockade on the same immune effector cell. AstraZeneca is currently advancing the drug in ...

As an investor, mistakes are inevitable. But really bad investments should be rare. So spare a thought for the long term shareholders of Compugen Ltd. (NASDAQ:CGEN); the share price is down a whopping ...

The FDA has temporarily blocked Compugen’s plans to start a phase 1 trial of PVRIG-targeting cancer drug COM701. Officials caused the delay by demanding to see additional CMC information before ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash ...

Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setting of platinum sensitive ovarian cancer "There is a gap in care ...

Gilead Sciences is uploading $60 million to Compugen’s bank account plus hefty milestones down the road in exchange for the rights to a preclinical IL-18 binding protein program that includes a solid ...

Compugen focuses on finding cancer-fighting therapies. The company is a clinical-stage biotech with little revenue. Compugen said it plans to present clinical data at an upcoming conference. The other ...